Inovio Pharmaceuticals Inc (NASDAQ: INO). Extremely significant negative changes in investment behavior have recently occurred: its longer term price trend turned down, and negative upside/downside volume developed.
Meaningful negative changes in Inovio Pharmaceuticals Inc (NASDAQ: INO) fundamentals have recently occurred: the stock’s power rating fell below 50, and significant quarterly sales deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
INO’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Inovio Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Inovio Pharmaceuticals has a poor Power Rating of 21 and a poor Appreciation Score of 18, and the Lowest Value Trend Rating results.
Recent Price Action
Inovio Pharmaceuticals Inc (NASDAQ: INO) stock closed at $5.62 on 10/1/24 after a decline of -2.8%. Moreover, trading volume in this decline was above average at 147% of normal. The stock has been weak relative to the market over the last nine months and has declined -4.3% during the last week.
Be the first to comment